New Horizon Health's revenue for the
six
months ended in Jun. 2023 was HK$900 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2023 was HK$1,502 Mil.
New Horizon Health's Revenue per Share for the
six
months ended in Jun. 2023 was HK$1.84.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was HK$3.26.
During the past 5 years, New Horizon Health's highest 3-Year average Revenue per Share Growth Rate was 138.10% per year. The lowest was 135.30% per year. And the median was 136.70% per year.
New Horizon Health Revenue Historical Data
The historical data trend for New Horizon Health's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of New Horizon Health's Revenue
For the Medical Devices subindustry, New Horizon Health's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Horizon Health's Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, New Horizon Health's Revenue distribution charts can be found below:
* The bar in red indicates where New Horizon Health's Revenue falls into.
New Horizon Health Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,502 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Horizon Health (HKSE:06606) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
New Horizon Health Revenue Related Terms
Thank you for viewing the detailed overview of New Horizon Health's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
New Horizon Health (HKSE:06606) Business Description
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06606 has been successfully added to your 